statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest on NKGen Biotech Inc (NASDAQ: NKGN) as shares surge 25.2% on high volume. Insights into NK cell therapy for neurodegenerative diseases. Developments in Parkinson's and Alzheimer's...

What's Going On With Nano-Cap NKGen Biotech Stock On Monday?

SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid ( CSF ) and plasma Tau proteins in Alzheimer's patients. The additional Phase 1 SNK01 trial data suggest...

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference

Acciones al alza
Aptorum Gr (NASDAQ:APM) experimentaron un repunte del 680,24% para establecerse en los 11,31 d lares durante la sesi n del regular del mi rcoles.
NKGen Biotech (NASDAQ:NKGN...

12 acciones de salud en movimiento en la sesi n intrad a del 06/03/2024

SANTA ANA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ( NKGen or the Company ), a clinical-stage biotechnology company focused on the development and...

NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference

NKGen Biotech (NKGN) has released an update. NKGen Biotech, Inc., once known as Graf Acquisition Corp. IV, has revised its deal with Meteora Capita...

NKGen Biotech Enhances Strategic Partnership with Meteora Capital

NKGen Biotech (NKGN) has released an update to notify the public and investors about an entry into a material definitive agreement. NKGen Biotech...

NKGen Biotech Amends Key Agreement, Increases Prepayment Shortfall

NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.

Watchers	945
52-Wk Low	$0.7802
52-Wk High	$12.88

Volume	49,256.00
52-Wk High	$12.88
52-Wk Low	$0.7802

NKGN NKGen Biotech Inc

About

Feed

News

Sentiment

Fundamentals